1. Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 2. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 3. Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 4. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
✉ Corresponding author: Dr Hideya Onishi, Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: ohnishi.hideya.928kyushu-u.ac.jp.
Citation:
Nagao S, Onishi H, Kawamoto M, Masuda S, Na L, Morisaki S, Iwamoto N, Yamada Y, Koga S, Ichimiya S, Nakayama K, Imaizumi A, Nakashima K, Oda Y, Nakamura M. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. J Cancer 2023; 14(2):306-317. doi:10.7150/jca.78993. https://www.jcancer.org/v14p0306.htm
In our comprehensive analysis of pancreatic cancer pathology, we found that the C4orf47 molecule was upregulated in hypoxic environments. C4orf47 is reported to be a centrosome-associated protein, but its biological significance in cancer is completely unknown; therefore, we assessed its role in pancreatic cancer. We found that C4orf47 was a direct target of HIF-1α and is upregulated in hypoxic conditions, in which it suppressed the cell cycle and inhibits cell proliferation through up-regulation of the cell cycle repressors Fbxw-7, P27, and p57; and the down-regulation of the cell cycle promoters c-myc, cyclinD1, and cyclinC. Furthermore, C4orf47 induced epithelial-mesenchymal transition and enhanced their cell plasticity and invasiveness. In addition, the p-Erk/p-p38 ratio was significantly enhanced and down-regulated CD44 expression by C4orf47 suppression, suggesting that C4orf47 is involved in pancreatic cancer dormancy under hypoxic conditions. Furthermore, the potential of C4orf47 expression was a good prognostic biomarker for pancreatic cancer. These results contribute to the elucidation of the pathology of refractory pancreatic cancer and the development of novel therapeutic strategies.
Keywords: dormancy, pancreatic cancer, hypoxia
Citation styles
APA
Nagao, S., Onishi, H., Kawamoto, M., Masuda, S., Na, L., Morisaki, S., Iwamoto, N., Yamada, Y., Koga, S., Ichimiya, S., Nakayama, K., Imaizumi, A., Nakashima, K., Oda, Y., Nakamura, M. (2023). C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. Journal of Cancer, 14(2), 306-317. https://doi.org/10.7150/jca.78993.
ACS
Nagao, S.; Onishi, H.; Kawamoto, M.; Masuda, S.; Na, L.; Morisaki, S.; Iwamoto, N.; Yamada, Y.; Koga, S.; Ichimiya, S.; Nakayama, K.; Imaizumi, A.; Nakashima, K.; Oda, Y.; Nakamura, M. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. J. Cancer 2023, 14 (2), 306-317. DOI: 10.7150/jca.78993.
NLM
Nagao S, Onishi H, Kawamoto M, Masuda S, Na L, Morisaki S, Iwamoto N, Yamada Y, Koga S, Ichimiya S, Nakayama K, Imaizumi A, Nakashima K, Oda Y, Nakamura M. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. J Cancer 2023; 14(2):306-317. doi:10.7150/jca.78993. https://www.jcancer.org/v14p0306.htm
CSE
Nagao S, Onishi H, Kawamoto M, Masuda S, Na L, Morisaki S, Iwamoto N, Yamada Y, Koga S, Ichimiya S, Nakayama K, Imaizumi A, Nakashima K, Oda Y, Nakamura M. 2023. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. J Cancer. 14(2):306-317.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Global reach, higher impact
